Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Y.S. Sherrer, D.A. Bloch, D.M. Mitchell, D.Y. Young, J.F. Fries.
The development of disability in rheumatoid arthritis.
Arthritis Rheum, 29 (1986), pp. 494-500
[2.]
Y. Matsuda, H. Yamanaka, K. Higami, S. Kashiwazaki.
Time lag between active joint inflammation and radiological progression in patients with early rheumatoid arthritis.
J Rheumatol, 25 (1998), pp. 427-432
[3.]
S.E. Gabriel, C.S. Crowson, W.M. O’Fallon.
Mortality in rheumatoid arthritis: have we made an impact in 4 decades?.
J Rheumatol, 26 (1999), pp. 2529-2533
[4.]
S.E. Gabriel, C.S. Crowson, W.M. O’Fallon.
The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985.
Arthritis Rheum, 42 (1999), pp. 415-420
[5.]
F. Wolfe, D.J. Hawley.
The longterm outcomes of rheumatoid arthritis: work disability: a prospective 18 year study of 823 patients.
J Rheumatol, 25 (1998), pp. 2108-2117
[6.]
F. Wolfe, D.M. Mitchell, J.T. Sibley, J.F. Fries, D.A. Bloch, C.A. Williams, et al.
The mortality of rheumatoid arthritis.
Arthritis Rheum, 37 (1994), pp. 481-494
[7.]
J. De La Mata, F.J. Blanco, J.J. Gomez-Reino.
Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients.
Ann Rheum Dis, 54 (1995), pp. 881-885
[8.]
G. Galindo-Rodriguez, J.A. Avina-Zubieta, A.S. Russell, M.E. Suarez-Almazor.
Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.
J Rheumatol, 26 (1999), pp. 2337-2343
[9.]
M.J. Plant, P.W. Jones, J. Saklatvala, W.E. Ollier, P.T. Dawes.
Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study.
J Rheumatol, 25 (1998), pp. 417-426
[10.]
M.J. Plant, A.L. Williams, M.M. O'Sullivan, P.A. Lewis, E.C. Coles, J.D. Jessop.
Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis.
Arthritis Rheum, 43 (2000), pp. 1473-1477
[11.]
G. Borg, E. Allander, B. Lund, E. Berg, U. Brodin, H. Petterson, et al.
Auranofin improves outcome in early rheumatoid arthritis. Results from a 2- year, double blind placebo controlled study.
J Rheumatol, 15 (1998), pp. 1747-1754
[12.]
The HERA study group.
A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study.
Am J Med, 98 (1995), pp. 156-168
[13.]
A. Van der Heide, J.W. Jacobs, J.W. Bijlsma, A.H. Heurkens, C. Van Booma-Frankfort, M.J. Van der Veen, The effectiveness of early treatment with “second-line” antirheumatic drugs, et al.
A randomized, controlled trial.
Ann Intern Med, 124 (1996), pp. 699-707
[14.]
J.J. Anderson, G. Wells, A.C. Verhoeven, D.T. Felson.
Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration.
Arthritis Rheum, 43 (2000), pp. 22-29
[15.]
V.P. Nell, K.P. Machold, G. Eberl, T.A. Stamm, M. Uffmann, J.S. Smolen.
Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.
Rheumatology, 43 (2004), pp. 906-914
[16.]
C. Grigor, H. Capell, A. Stirling, A.D. McMahon, P. Lock, R. Vallance, et al.
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.
Lancet, 364 (2004), pp. 263-269
[17.]
Y.P.M. Goekoop-Ruiterman, J.K. De Vries-Bouwstra, C.F. Allaart, D. Van Zeben, P.J.S.M. Kerstens, J.M.W. Hazes, et al.
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study).
Arthritis Rheum, 52 (2005), pp. 3381-3390
[18.]
J.L. Andreu-Sánchez, J. Sanz-Sanz, P. Muñoz-Carreño, L. Silva-Fernández.
Tratamientos combinados en la artritis reumatoide.
Semin Fund Esp Reumatol, 6 (2005), pp. 151-161
[19.]
C. Egsmose, B. Lund, G. Borg, H. Pettersson, E. Berg, U. Brodin, et al.
Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow up of a prospective double blind placebo controlled study.
J Rheumatol, 22 (1995), pp. 2208-2213
[20.]
E. Tsakonas, A.A. Fitzgerald, M.A. Fitzcharles, A. Cividino, J.C. Thorne, A. M'Seffar, et al.
Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study.
J Rheumatol, 27 (2000), pp. 623-629
[21.]
C.J. Haagsma, P.L. Van Riel, A.J. De Jong, L.B. Van de Putte.
Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial.
Br J Rheumatol, 36 (1997), pp. 1082-1088
[22.]
M. Dougados, B. Combe, A. Cantagrel, P. Goupille, P. Olive, M. Chattenkirchner, et al.
Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components.
Ann Rheum Dis, 58 (1999), pp. 220-225
[23.]
M. Boers, A.C. Verhoeven, H.M. Markusse, M.A. Van de Laar, R. Westhovens, J.C. Van Denderen, et al.
Randomised comparison of combined stepdown prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Lancet, 350 (1997), pp. 309-318
[24.]
R.B. Landewe, M. Boers, A.C. Verhoeven, R. Westhovens, M.A. Van de Laar, H.M. Markusse, et al.
COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention.
Arthritis Rheum, 46 (2002), pp. 347-356
[25.]
T. Möttönen, P. Hannonen, M. Leirisalo-Repo, M. Nissila, H. Kautiainen, M. Korpela, et al.
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Lancet, 353 (1999), pp. 1568-1573
[26.]
M. Korpela, L. Laasonen, P. Hannonen, H. Kautiainen, M. Leirisalo-Repo, M. Hakala, et al.
Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study.
Arthritis Rheum, 50 (2004), pp. 2072-2081
[27.]
K. Puolakka, H. Kautiainen, T. Mottonen, P. Hannonen, M. Korpela, H. Julkunen, et al.
Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
Arthritis Rheum, 50 (2004), pp. 55-62
[28.]
K. Puolakka, H. Kautiainen, T. Mottonen, P. Hannonen, M. Korpela, M. Hakala, et al.
Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
Arthritis Rheum, 52 (2005), pp. 36-41
[29.]
M. Calguneri, S. Pay, Z. Caliskaner, S. Apras, S. Kiraz, I. Ertenli, et al.
Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis.
Clin Exp Rheumatol, 17 (1999), pp. 699-704
[30.]
S.M. Proudman, P.G. Conaghan, C. Richardson, B. Griffiths, M.J. Green, D. McGonagle, et al.
Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone.
Arthritis Rheum, 43 (2000), pp. 1809-1819
[31.]
A. Marchesoni, N. Battafarano, M. Arreghini, B. Panni, M. Gallazzi, S. Tosi.
Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone.
Rheumatology, 42 (2003), pp. 1545-1549
[32.]
A.H. Gerards, R.B. Landewe, A.P. Prins, G.A. Bruyn, H.S. Goei The, R.F. Laan, et al.
Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial.
Ann Rheum Dis, 62 (2003), pp. 291-296
[33.]
P. Sarzi-Puttini, E. D’Ingianna, M. Fumagalli, M. Scarpellini, T. Fiorini, E.L. Cherie-Ligniere, et al.
An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis.
Rheumatol Int, 25 (2005), pp. 15-22
[34.]
J.R. O’Dell, C.E. Haire, N. Erikson, W. Drymalski, W. Palmer, P.J. Eckhoff, et al.
Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
N Engl J Med, 334 (1996), pp. 1287-1291
[35.]
J.R. O’Dell, R. Leff, G. Paulsen, C. Haire, J. Mallek, P.J. Eckhoff, et al.
Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications. Results of a two-year, randomized, double-blind, placebo-controlled trial.
Arthritis Rheum, 46 (2002), pp. 1164-1170
[36.]
P. Tugwell, T. Pincus, D. Yocum, M. Stein, O. Gluck, G. Kraag, et al.
Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group.
N Engl J Med, 333 (1995), pp. 137-141
[37.]
J.M. Kremer, M.C. Genovese, G.W. Cannon, R. Caldwell, J.J. Cush, D.E. Furst, et al.
Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double- blind, placebo-controlled trial.
Ann Intern Med, 137 (2002), pp. 726-733
[38.]
A.J. Lehman, J.M. Esdaile, A.V. Klinkhoff, E. Grant, A. Fitzgerald, J. Canvin, METGO Study Group.
A 48-week, randomized, double-blind, doubleobserver, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study.
Arthritis Rheum, 52 (2005), pp. 1360-1370
[39.]
J.R. Kirwan.
The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group.
N Engl J Med, 333 (1995), pp. 142-146
[40.]
P. Hickling, R.K. Jacoby, J.R. Kirwan.
Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group.
Br J Rheumatol, 37 (1998), pp. 930-936
[41.]
A.A. Van Everdingen, J.W. Jacobs, D.R. Siewertsz Van Reesema, J.W. Bijlsma.
Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial.
Ann Intern Med, 136 (2002), pp. 1-12
[42.]
H.A. Capell, R. Madhok, J.A. Hunter, D. Porter, E. Morrison, J. Larkin, et al.
Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial.
Ann Rheum Dis, 63 (2004), pp. 797-803
[43.]
B. Svensson, A. Boonen, K. Albertsson, D. Van der Heijde, C. Keller, I. Hafstrom.
Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
Arthritis Rheum, 52 (2005), pp. 3360-3370
[44.]
S. Wassenberg, R. Rau, P. Steinfeld, H. Zeidler.
Very-low dose prednisone in early rheumatoid arthritis retards radiographic progression over to years: a multicenter, double-blind, placebo-controlled trial.
Arthritis Rheum, 52 (2005), pp. 3371-3380
[45.]
R.F. Willkens, J.T. Sharp, D. Stablein, C. Marks, R. Wortmann.
Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment.
Arthritis Rheum, 38 (1995), pp. 1799-1806
[46.]
M.B. Ferraz, G.R. Pinheiro, M. Helfenstein, E. Albuquerque, C. Rezende, L. Roimicher, et al.
Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomized placebo-controlled trial.
Scand J Rheumatol, 23 (1994), pp. 231-236
[47.]
C.J. Haagsma, P.L. Van Riel, D.J. De Rooij, T.B. Vree, F.J. Russel, M.A. Van’t Hof, et al.
Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy.
Br J Rheumatol, 33 (1994), pp. 1049-1055
Copyright © 2006. Elsevier España S.L. Barcelona
